Changes in Normal Liver and Spleen Volume after Radioembolization with {sup 90}Y-Resin Microspheres in Metastatic Breast Cancer Patients: Findings and Clinical Significance

Journal Article · Sat Oct 15 00:00:00 EDT 2011 · Cardiovascular and Interventional Radiology

DOI:https://doi.org/10.1007/S00270-011-0217-8· OSTI ID:21608588

Schmidt, G P; Trumm, C G; Hoffmann, R T; Reiser, M F; Jakobs, T F ^[1]

---

1. Ludwig-Maximilians-University of Munich, University Hospitals Munich, Department of Clinical Radiology (Germany)

Purpose: In clinical trials with yttrium-90-resin-microspheres for the management of colorectal cancer liver metastases, it was observed that radioembolization might result in splenomegaly and an increase in portal vein size. Subclinical hepatitis in normal liver tissue as well as the effects of radioembolization and prior chemotherapy are suspected to be responsible for this phenomenon. The purpose of this study was to quantify the changes in liver and spleen volume and portal vein diameter after radioembolization. Methods: Twenty-seven patients with liver-dominant metastatic disease from breast cancer who had not responded to chemotherapy or had to abandon chemotherapy because of its toxic effects were evaluated. Changes in liver and spleen volume and portal vein diameter as well as liver tumor volume and diameter were quantified using computed tomography scans. Results: Radioembolization was associated with a significant mean decrease in the whole liver volume of 10.2% (median 16.7%; P = 0.0024), mainly caused by a reduction in the right lobe volume (mean 16.0%; P < 0.0001). These changes were accompanied by a significant increase in the diameter of the main portal vein (mean 6.8%; P < 0.0001) as well as splenic volume (mean 50.4%; P < 0.0001). Liver-tumor volume and diameter decreased by a median of 24 and 39.7%. Conclusions: Radioembolization is an effective treatment for tumor size reduction in patients with breast cancer liver metastases. Treatment is associated with changes of hepatic parenchymal volume, splenic volume, and portal vein size that appear not to represent clinically important sequelae in this patient cohort.

• OSTI ID: 21608588
• Journal Information: Cardiovascular and Interventional Radiology, Vol. 34, Issue 5; Other Information: DOI: 10.1007/s00270-011-0217-8; Copyright (c) 2011 Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); Country of input: International Atomic Energy Agency (IAEA); ISSN 0174-1551
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
CHEMOTHERAPY
CLINICAL TRIALS
COMPUTERIZED TOMOGRAPHY
HEPATITIS
LIVER
MAMMARY GLANDS
METASTASES
MICROSPHERES
NEOPLASMS
PATIENTS
RESINS
SPLEEN
SPLENOMEGALY
TOXICITY
VEINS
YTTRIUM 90
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BLOOD VESSELS
BODY
CARDIOVASCULAR SYSTEM
DAYS LIVING RADIOISOTOPES
DIAGNOSTIC TECHNIQUES
DIGESTIVE SYSTEM
DIGESTIVE SYSTEM DISEASES
DISEASES
GLANDS
HOURS LIVING RADIOISOTOPES
INTERMEDIATE MASS NUCLEI
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
MEDICINE
NUCLEI
ODD-ODD NUCLEI
ORGANIC COMPOUNDS
ORGANIC POLYMERS
ORGANS
PATHOLOGICAL CHANGES
PETROCHEMICALS
PETROLEUM PRODUCTS
POLYMERS
RADIOISOTOPES
SYMPTOMS
TESTING
THERAPY
TOMOGRAPHY
YTTRIUM ISOTOPES